BCTX BriaCell Therapeutics Corp

Price (delayed)

$3.255

Market cap

$23.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$18.52

Enterprise value

-$6.3M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Highlights
The EPS has surged by 63% year-on-year and by 53% since the previous quarter
The net income has shrunk by 154% YoY and by 3.3% QoQ

Key stats

What are the main financial stats of BCTX

BCTX stock price

How has the BriaCell Therapeutics stock price performed over time
Intraday
-1.66%
1 week
-9.08%
1 month
-20.42%
1 year
-90.11%
YTD
-54.22%
QTD
-22.32%

Financial performance

How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.74M
Net income
-$30.04M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 154% YoY and by 3.3% QoQ
The company's operating income fell by 13% YoY

Price vs fundamentals

How does BCTX's price correlate with its fundamentals

Growth

What is BriaCell Therapeutics's growth rate over time

Valuation

What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
0.2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 63% year-on-year and by 53% since the previous quarter
The P/B is 79% less than the last 4 quarters average of 1.0

Efficiency

How efficient is BriaCell Therapeutics business performance
The return on equity has increased by 37% since the previous quarter
BCTX's ROA is up by 26% since the previous quarter and by 5% year-on-year
BriaCell Therapeutics's ROIC has increased by 7% from the previous quarter

Dividends

What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCTX.

Financial health

How did BriaCell Therapeutics financials performed over time
BriaCell Therapeutics's current ratio has surged by 195% QoQ
The total assets has soared by 157% since the previous quarter
The debt is 100% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.